Professor of Medicine, Weill Cornell Medical School, Director Houston Methodist Cancer Center
Oncology
Dr. Jenny C. Chang, MD
|
|
Give Review
Jenny Chang works in the field of Oncology. She graduated from University of Cambridge School of Medicine. She has 3 awards "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Jenny Chang is a published doctor. She published 46 publications, including: 'Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival.' Jenny Chang accepts all Medicare patients.
Publications
- Phosphatase PTP4A3 promotes triple-negative Breast cancer growth and predicts poor patient survival.
- Inhibition of iNOS as a novel effective targeted therapy against triple negative Breast cancer.
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer.
- Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in Breast cancer by inhibiting nitric oxide synthase signaling.
- Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the Breast.
- Chloroquine eliminates Cancer stem cells through deregulation of Jak2 and DNMT1.
- XBP1 promotes triple-negative Breast cancer by controlling the HIF1α pathway.
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
- Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts.
- Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer.
- A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human Breast cancer xenograft models.
- Studying Cancer Stem Cell Dynamics on PDMS Surfaces for Microfluidics Device Design.
- Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Recep...
- Delivery of gene silencing agents for Breast cancer therapy.
- Modeling of nanotherapeutics deLivery based on tumor perfusion.
- Prognostic markers for invasive micropapillary carcinoma of the Breast: a population-based analysis.
- Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors.
- Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors.
- Patient-derived Breast tumor xenografts facilitating personalized cancer therapy.
- Selective small molecule stat3 inhibitor reduces Breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.
- A gene transcription signature of obesity in Breast cancer.
- Stat5: from Breast development to cancer prognosis, prediction, and progression.
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy.
- Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-over...
- Thermal enhancement with optically activated gold nanoshells sensitizes Breast cancer stem cells to radiation therapy.
- Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in Breast cancer.
- Residual Breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
- Intrinsic resistance of tumorigenic Breast cancer cells to chemotherapy.
- ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
- HER2 inhibition: from discovery to clinical practice.
- Molecular heterogeneity of inflammatory Breast cancer: a hyperproliferative phenotype.
- Apoptosis induction by the core biopsy procedure.
- Neoadjuvant trastuzumab induces apoptosis in primary Breast cancers.
- Patterns of resistance and incomplete response to docetaxel by gene expression profiling in Breast cancer patients.
- Neoadjuvant trastuzumab and docetaxel in Breast cancer: preliminary results.
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with Breast cancer.
- Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in Breast cancer patients.
- Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
- Pharmacogenetics of Breast cancer: toward the individualization of therapy.
- Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic Breast density.
- Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced Breast cancers.
- The promise of microarrays in the management and treatment of Breast cancer.
- Genomic approaches to understanding and treating Breast cancer.
- Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats.
- Use of proteomic differential displays to assess functional discrepancies and adjustments of human bone marrow- and Wharton jelly-derived mesenchymal stem cells.
Schools
University Of Cambridge
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Breast Cancer
- Liver Cancer
- Lung Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
University of Cambridge School of Medicine
Drug Facts
| NPI NUMBER | 1487734810 | |
| NPPES Provider LastName | CHANG | |
| NPPES Provider FirstName | JENNY | |
| NPPES Provider ZIPCode | 770302717 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 611.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 35.0 | |
| Percent Opioid Claims | 5.73 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487734810 |
| Last Name Of The Provider | CHANG |
| First Name Of The Provider | JENNY |
| View All |
Similar Doctors
|
|
Dr. Uday R. Popat, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jianjun Gao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivien A. Sheehan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John O. Mendelsohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco Vega-Vazquez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shi-Ming Tu, MD |
|
|
Dr. Renata Ferrarotto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Andreeff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Cathy Eng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mindy Hsiong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Filip Janku, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Yanyan Lou, MD |
|
|
Dr. Jeffrey J. Molldrem, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Aaron J. Schueneman, MD
This Doctor is OpenDoctor Recommended.
|